In recent years, there has been an increased awareness of the importance of considering lower urinary tract symptoms (LUTS) as a global term. Under this umbrella term, disorders of bladder function can be most effectively considered as failure to store or failure to empty. We now clearly recognise the misconceptions inherent in the assumptions that all LUTS in men are caused by benign prostatic...

The main purpose of this chapter is to feel the close relationship between the female genital tract and the lower urinary tract (LUT) that leads to clinical dysfunctions that can impact either one and cause symptoms with increased severity or significance than the initially affected. A representative example of this would be the Painful Urethral Syndrome, which can cause severe dyspareunia that...

DISEASE OVERVIEW Urinary incontinence (UI) may be defined as any involuntary or abnormal urine loss. UI is characterized by lower urinary tract symptoms (LUTS), which include both storage and voiding problems. UI can be further defined by the patient’s presentations and symptoms. Urge urinary incontinence (UUI) is defined as involuntary urine leakage associated with urgency. Stress urinary inco...

PURPOSE OF REVIEW Incontinence is not an isolated symptom in men, but rather a component of a multifactorial problem that may include other lower urinary tract symptoms (LUTS). Male urinary incontinence is often seen following prostate surgery and procedures, particularly prostate cancer surgery. Men with enlarged prostates experience overactive bladder symptoms of urgency and frequency. Despit...

BACKGROUND Progressive aging- and inflammation-associated fibrosis effectively remodels the extracellular matrix (ECM) to increase prostate tissue stiffness and reduce urethral flexibility, resulting in urinary flow obstruction and lower urinary tract symptoms (LUTS). In the current study, we sought to test whether senescence-accelerated mouse prone (SAMP)6 mice, which were reported to develop ...

OBJECTIVE In patients with prostate cancer (PCa), prostate enlargement may give rise to lower urinary tract symptoms (LUTS); many patients suffer from moderate-to-severe symptoms. We compare the efficacy of degarelix and goserelin plus bicalutamide in improving LUTS in PCa patients. METHODS Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks ...

Symptoms examined in a level 1 assessment In the report The Standardisation of Terminology of Lower Urinary Tract Function, Abrams at al (2002) divide lower urinary tract symptoms (LUTs) into three groups: ■ Storage symptoms – experienced when urine is stored in the bladder. These include increased daytime frequency and nocturia (Box 1); ■ Voiding symptoms – these include a slow urinary stream,...

Hypothesis / aims of study There is increasing evidence showing that prostatic inflammation is associated with the development of histological benign prostatic hyperplasia (BPH) and male lower urinary tract symptoms (LUTS) [1]. It has also been reported that dutasteride, which inhibits 5α-reductase, might have anti-inflammatory effects in the prostate of patients with lower urinary tract sympto...

A PHASE II STUDY ASSESSING THE SAFETY AND EFFICACY OF A SINGLE TREATMENT OF 100 U, 200 U, or 300 U BOTOX® COMPARED WITH PLACEBO INJECTED INTO THE PROSTATE TO TREAT LOWER URINARY TRACT SYMPTOMS (LUTS) IN PATIENTS DUE TO BENIGN PROSTATIC HYPERPLASIA Trial ID: 191622-517-05 Coordination: CMX Research Inc. Trial design: A phase II study assessing the safety and effi cacy of a single treatment of BO...